Liste modèle des médicaments essentiels

Amikacin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 50 mg per mL in 2 mL vial (as sulfate); 250 mg per mL in 2 mL vial (as sulfate) ◦ Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate) ◦ Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)	**Premier choix** Neutropaenia (high-risk) co-prescrite avec cefotaxime Acute pyelonephritis (severe) co-prescrite avec cefotaxime Inflammatory or other diseases of prostate (severe) co-prescrite avec ceftriaxone Acute pyelonephritis (severe) co-prescrite avec ceftriaxone Inflammatory or other diseases of prostate (severe)
Antituberculosis medicines ◦ Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)	Multi-drug resistant Mycobacterium tuberculosis

Amoxicillin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid ◦ Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection ◦ Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate) ◦ Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate) ◦ Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate) ◦ Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid	**Premier choix** Acute pharyngitis Periapical abscess without sinus Acute sinusitis Acute otitis media Chronic obstructive pulmonary disease with acute exacerbation Acute malnutrition in infants, children or adolescents (uncomplicated) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec gentamicin Sepsis without septic shock **Second choix** Bacterial meningitis **Autres indications** Bacterial infection of unspecified site Infectious cystitis

Amoxicillin + clavulanic acid

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection ◦ Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid ◦ Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt) ◦ Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt) ◦ Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)	**Premier choix** Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Acute sinusitis Other specified pneumonia (Hospital-acquired pneumonia) Chronic obstructive pulmonary disease with acute exacerbation Neutropaenia (low-risk) Peritoneal abscess (mild-moderate) Peritonitis (mild-moderate) Infectious cystitis Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Bacterial pneumonia (Community-acquired pneumonia - severe) Bacterial infection of joint Acute otitis media Other specified prophylactic measures Osteomyelitis or osteitis **Autres indications** Bacterial infection of unspecified site
Antituberculosis medicines ◦ Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid ◦ Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt) ◦ Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)	Multi-drug resistant Mycobacterium tuberculosis

Ampicillin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection ◦ Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension ◦ Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)	**Premier choix** Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec gentamicin Sepsis without septic shock co-prescrite avec gentamicin Peritoneal abscess (mild-moderate) co-prescrite avec gentamicin Peritoneal abscess (severe) co-prescrite avec gentamicin Peritonitis (mild-moderate) co-prescrite avec gentamicin Peritonitis (severe) **Second choix** Bacterial meningitis **Autres indications** Bacterial infection of unspecified site

Azithromycin

Section	Indications
Watch group antibiotics ◦ Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid ◦ Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)	**Premier choix** Cholera Cholera [children] Paratyphoid fever Chlamydia trachomatis Typhoid fever Yaws Trachoma co-prescrite avec ceftriaxone Gonococcal infection **Second choix** Infectious gastroenteritis or colitis without specification of infectious agent co-prescrite avec cefixime Gonococcal infection

Aztreonam

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection	Other specified bacterial diseases

Bedaquiline

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > tablet: 100 mg tablet; 20 mg tablet	Multi-drug resistant Mycobacterium tuberculosis

Benzathine benzylpenicillin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IM: 1.2 million IU in vial (≈ 900 mg) powder for injection; 2.4 million IU in vial (≈ 1.8 g) powder for injection	**Premier choix** Congenital syphilis [children] Syphilis **Autres indications** Bacterial infection of unspecified site

Benzylpenicillin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt) ◦ Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)	**Premier choix** Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Congenital syphilis [children] Syphilis co-prescrite avec gentamicin Sepsis without septic shock **Second choix** Bacterial meningitis **Autres indications** Bacterial infection of unspecified site

Capreomycin

Section	Indications
Antituberculosis medicines ◦ Parenteral > General injections > IV: 1000 mg powder for injection (vial)	Multi-drug resistant Mycobacterium tuberculosis

Cefalexin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid ◦ Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate) ◦ Oral > Solid > dispersible tablet: 125 mg; 250 mg ◦ Oral > Solid: 250 mg (as monohydrate)	**Premier choix** Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Chronic obstructive pulmonary disease with acute exacerbation Acute pharyngitis **Autres indications** Bacterial infection of unspecified site

Cefazolin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection	**Premier choix** Other specified prophylactic measures co-prescrite avec metronidazole Other specified prophylactic measures **Second choix** Bacterial infection of joint Osteomyelitis or osteitis **Autres indications** Surgical site infection

Cefepime

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection	Other specified bacterial diseases

Cefiderocol

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection	Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli

Cefixime

Section	Indications
Watch group antibiotics ◦ Oral > Liquid: 100 mg per 5 mL powder for oral liquid ◦ Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)	**Second choix** Infectious gastroenteritis or colitis without specification of infectious agent co-prescrite avec azithromycin Gonococcal infection

Cefotaxime

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)	**Premier choix** Acute pyelonephritis (severe) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Bacterial pneumonia (Community-acquired pneumonia - severe) Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis co-prescrite avec amikacin Inflammatory or other diseases of prostate (severe) co-prescrite avec metronidazole Peritoneal abscess (mild-moderate) co-prescrite avec metronidazole Peritoneal abscess (severe) co-prescrite avec metronidazole Peritonitis (mild-moderate) co-prescrite avec metronidazole Peritonitis (severe) **Second choix** Acute pyelonephritis (mild to moderate) Sepsis without septic shock Bacterial infection of joint Inflammatory or other diseases of prostate (mild to moderate) Osteomyelitis or osteitis **Autres indications** Bacterial infection of unspecified site

Ceftaroline

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection	Other specified bacterial diseases

Ceftazidime

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection	**Premier choix** Endophthalmitis **Autres indications** Pseudomonas aeruginosa resistant to other antibiotic

Ceftazidime + avibactam

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection	Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli

Ceftolozane + tazobactam

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 1 g + 0.5 g powder for injection	Carbapenem-resistant Pseudomonas aeruginosa

Ceftriaxone

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)	**Premier choix** Other specified pneumonia (Hospital-acquired pneumonia) Acute pyelonephritis (severe) Paratyphoid fever Typhoid fever Endophthalmitis Bacterial pneumonia (Community-acquired pneumonia - severe) Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

◦ Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)	Bacterial meningitis co-prescrite avec amikacin Inflammatory or other diseases of prostate (severe) co-prescrite avec azithromycin Gonococcal infection co-prescrite avec metronidazole Necrotising fasciitis co-prescrite avec metronidazole Peritoneal abscess (mild-moderate) co-prescrite avec metronidazole Peritoneal abscess (severe) co-prescrite avec metronidazole Peritonitis (mild-moderate) co-prescrite avec metronidazole Peritonitis (severe) **Second choix** Acute pyelonephritis (mild to moderate) Bacterial infection of joint Sepsis without septic shock Infectious gastroenteritis or colitis without specification of infectious agent Inflammatory or other diseases of prostate (mild to moderate) Osteomyelitis or osteitis **Autres indications** Bacterial infection of unspecified site

Cefuroxime

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection	**Second choix** Other specified prophylactic measures

Chloramphenicol

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate) ◦ Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection ◦ Oral > Liquid: 150 mg per 5 mL (as palmitate) ◦ Oral > Solid: 250 mg capsule	**Second choix** Bacterial meningitis **Autres indications** Bacterial infection of unspecified site

Ciprofloxacin

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 2 mg per mL (as hyclate) ◦ Oral > Liquid: 250 mg per 5 mL (anhydrous) ◦ Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride) ◦ Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride) ◦ Oral > Solid: 250 mg (as hydrochloride)	**Premier choix** Acute pyelonephritis (mild to moderate) Paratyphoid fever Typhoid fever Infectious gastroenteritis or colitis without specification of infectious agent Neutropaenia (low-risk) Inflammatory or other diseases of prostate (mild to moderate) **Second choix** Cholera Cholera [children] co-prescrite avec metronidazole Peritoneal abscess (mild-moderate) co-prescrite avec metronidazole Peritonitis (mild-moderate) **Autres indications** Bacterial infection of unspecified site

Clarithromycin

Section	Indications
Watch group antibiotics ◦ Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid ◦ Parenteral > General injections > unspecified: 500 mg in vial powder for injection ◦ Oral > Solid > dosage form: 500 mg; 250 mg ◦ Oral > Solid > dosage form: 500 mg	**Premier choix** co-prescrite avec cefotaxime Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescrite avec ceftriaxone Bacterial pneumonia (Community-acquired pneumonia - severe) **Second choix** Acute pharyngitis co-prescrite avec amoxicillin + clavulanic acid Bacterial pneumonia (Community-acquired pneumonia - severe) **Autres indications** Helicobacter pylori associated gastric ulcer

Clindamycin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate) ◦ Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride) ◦ Oral > Solid: 150 mg (as hydrochloride) ◦ Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride) ◦ Oral > Solid: 150 mg (as hydrochloride) capsule ◦ Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection	**Premier choix** Necrotising fasciitis **Second choix** Bacterial infection of joint Osteomyelitis or osteitis **Autres indications** Bacterial infection of unspecified site

Clofazimine

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dosage form: 100 mg; 50 mg	Multi-drug resistant Mycobacterium tuberculosis
Antileprosy medicines ◦ Oral > Solid > dosage form: 100 mg; 50 mg	Leprosy

Cloxacillin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid ◦ Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection ◦ Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt) ◦ Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid ◦ Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule ◦ Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection	**Premier choix** Bacterial infection of joint Osteomyelitis or osteitis Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Sepsis without septic shock **Autres indications** Bacterial infection of unspecified site

Colistin (injection)

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) ◦ Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)	Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli

Cycloserine

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dosage form: 250 mg; 125 mg	Multi-drug resistant Mycobacterium tuberculosis

Dapsone

Section	Indications
Antileprosy medicines ◦ Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet	Leprosy

Daptomycin

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection	Other specified bacterial diseases

Delafloxacin

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 300 mg lyophilized powder for injection ◦ Oral > Solid: 450 mg	Methicillin resistant Staphylococcus aureus

Delamanid

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 25 mg ◦ Oral > Solid > tablet: 50 mg	Multi-drug resistant Mycobacterium tuberculosis

Dicloxacillin

Section	Indications
Access group antibiotics	**Premier choix** Therapeutic equivalent to cloxacillin pour Bacterial infection of joint Therapeutic equivalent to cloxacillin pour Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin pour Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Therapeutic equivalent to cloxacillin pour Sepsis without septic shock

Doxycycline

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium) ◦ Parenteral > General injections > unspecified: 100 mg in vial powder for injection ◦ Oral > Solid > dispersible tablet: 100 mg (as monohydrate) ◦ Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate) ◦ Oral > Solid > dosage form: 100 mg (as hyclate) ◦ Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous) ◦ Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)	**Premier choix** Cholera Chlamydia trachomatis **Second choix** Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Cholera [children] Chronic obstructive pulmonary disease with acute exacerbation **Autres indications** Bacterial infection of unspecified site

Eravacycline

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 50 mg lyophilized powder for injection	Other carbapenem resistant Enterobacterales

Erythromycin

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate) ◦ Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate) ◦ Oral > Solid: 250 mg (as stearate or ethylsuccinate)	**Second choix** Therapeutic equivalent to clarithromycin pour Acute pharyngitis **Autres indications** Bacterial infection of unspecified site

Ethambutol

Section	Indications
Antituberculosis medicines ◦ Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL ◦ Oral > Solid > dispersible tablet: 100 mg ◦ Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)	Other specified tuberculosis Tuberculosis

Ethambutol + isoniazid

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 400 mg + 150 mg tablet	Tuberculosis

Ethambutol + isoniazid + pyrazinamide + rifampicin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet	Tuberculosis

Ethambutol + isoniazid + rifampicin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 275 mg + 75 mg + 150 mg tablet	Tuberculosis

Ethionamide

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 125 mg ◦ Oral > Solid > tablet: 250 mg	Tuberculous meningitis Multi-drug resistant Mycobacterium tuberculosis

Fifth generation cephalosporins

Section	Indications
Reserve group antibiotics ◦ .	Other specified bacterial diseases

Flomoxef

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection	Other specified other antibiotic resistant Enterobacterales

Flucloxacillin

Section	Indications
Access group antibiotics	**Premier choix** Therapeutic equivalent to cloxacillin pour Bacterial infection of joint Therapeutic equivalent to cloxacillin pour Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin pour Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Therapeutic equivalent to cloxacillin pour Sepsis without septic shock

Fosfomycin (injection)

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection	Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales

Fourth generation cephalosporins

Section	Indications
Watch group antibiotics ◦ .	Other specified bacterial diseases

Gatifloxacin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 200 mg; 400 mg	Multi-drug resistant Mycobacterium tuberculosis

Gentamicin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)	**Premier choix** Neonatal meningitis Sepsis without septic shock Sepsis without septic shock Sepsis without septic shock co-prescrite avec amoxicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec ampicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicillin Peritoneal abscess (mild-moderate) co-prescrite avec ampicillin Peritoneal abscess (severe) co-prescrite avec ampicillin Peritonitis (mild-moderate) co-prescrite avec ampicillin Peritonitis (severe) co-prescrite avec benzylpenicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec benzylpenicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] **Second choix** Other specified prophylactic measures Gonococcal infection **Autres indications** Bacterial infection of unspecified site

Imipenem + cilastatin

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection	**Second choix** Therapeutic equivalent to meropenem pour Peritoneal abscess (severe) Therapeutic equivalent to meropenem pour Neutropaenia (high-risk) Therapeutic equivalent to meropenem pour Peritonitis (severe) **Autres indications** Pseudomonas aeruginosa resistant to other antibiotic Antibiotic resistant Acinetobacter baumannii
Antituberculosis medicines	Therapeutic equivalent to meropenem pour Multi-drug resistant Mycobacterium tuberculosis

Imipenem + cilastatin + relebactam

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection ◦ Parenteral > General injections > IV: 500 mg (as monohydrate) + 500 mg (as sodium) + 250 mg (as monohydrate) powder for injection	Other specified other antibiotic resistant Enterobacterales Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales

Isoniazid

Section	Indications
Antituberculosis medicines ◦ Parenteral > General injections > IV: 100 mg per mL ◦ Oral > Solid > dispersible tablet: 100 mg (scored) ◦ Oral > Solid > tablet: 100 mg; 300 mg	Other specified tuberculosis Tuberculosis

Isoniazid + pyrazinamide + rifampicin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg	Tuberculosis

Isoniazid + rifampicin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 50 mg + 75 mg ◦ Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg	Tuberculosis

Isoniazid + rifapentine

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 300 mg + 300 mg tablet (scored)	Latent tuberculosis

Kanamycin (injection)

Section	Indications
Antituberculosis medicines ◦ Parenteral > General injections > IV: 1000 mg powder for injection (vial)	Multi-drug resistant Mycobacterium tuberculosis

Levofloxacin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 100 mg ◦ Oral > Solid > tablet: 250 mg; 500 mg; 750 mg	Multi-drug resistant Mycobacterium tuberculosis

Linezolid

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 2 mg per mL in 300 mL bag ◦ Oral > Liquid: 100 mg per 5 mL powder for oral liquid ◦ Oral > Solid: 400 mg tablet; 600 mg tablet ◦ Oral > Solid > dispersible tablet: 150 mg ◦ Oral > Solid > tablet: 600 mg	Other specified bacterial diseases Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 150 mg (scored) ◦ Oral > Solid > tablet: 600 mg	Multi-drug resistant Mycobacterium tuberculosis

Meropenem

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	**Second choix** Neonatal meningitis Peritoneal abscess (severe) Neutropaenia (high-risk) Peritonitis (severe)
Antituberculosis medicines ◦ Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	Multi-drug resistant Mycobacterium tuberculosis

Meropenem + vaborbactam

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection	Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Acinetobacter baumannii Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli

Meticillin

Section	Indications
Access group antibiotics	**Premier choix** Therapeutic equivalent to cloxacillin pour Bacterial infection of joint Therapeutic equivalent to cloxacillin pour Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin pour Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Therapeutic equivalent to cloxacillin pour Sepsis without septic shock

Metronidazole

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 200 mg per 5 mL (as benzoate) ◦ Local > Rectal > Suppository: 500 mg; 1 g ◦ Parenteral > General injections > unspecified: 500 mg per 100 mL in vial ◦ Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg ◦ Oral > Solid > tablet: 500 mg; 200 mg; 250 mg; 400 mg ◦ Oral > Solid: 200 to 500 mg tablet ◦ Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection	**Premier choix** Trichomoniasis Intestinal infections due to Clostridioides difficile Necrotising fasciitis co-prescrite avec cefazolin Other specified prophylactic measures co-prescrite avec cefotaxime Peritoneal abscess (mild-moderate) co-prescrite avec cefotaxime Peritoneal abscess (severe) co-prescrite avec cefotaxime Peritonitis (mild-moderate) co-prescrite avec cefotaxime Peritonitis (severe) co-prescrite avec ceftriaxone Peritoneal abscess (mild-moderate) co-prescrite avec ceftriaxone Peritoneal abscess (severe) co-prescrite avec ceftriaxone Peritonitis (mild-moderate) co-prescrite avec ceftriaxone Peritonitis (severe) **Second choix** co-prescrite avec ciprofloxacin Peritoneal abscess (mild-moderate) co-prescrite avec ciprofloxacin Peritonitis (mild-moderate) **Autres indications** Bacterial infection of unspecified site

Moxifloxacin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 100 mg ◦ Oral > Solid > tablet: 400 mg	Multi-drug resistant Mycobacterium tuberculosis Tuberculosis

Nafcillin

Section	Indications
Access group antibiotics	**Premier choix** Therapeutic equivalent to cloxacillin pour Bacterial infection of joint Therapeutic equivalent to cloxacillin pour Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin pour Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Therapeutic equivalent to cloxacillin pour Sepsis without septic shock

Nitrofurantoin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 25 mg per 5 mL oral liquid ◦ Oral > Solid > dosage form: 100 mg; 50 mg	**Premier choix** Infectious cystitis

Ofloxacin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 200 mg; 400 mg	Multi-drug resistant Mycobacterium tuberculosis

Omadacycline

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 100 mg lyophilized powder for injection ◦ Oral > Solid: 300 mg	Methicillin resistant Staphylococcus aureus

Oxacillin

Section	Indications
Access group antibiotics	**Premier choix** Therapeutic equivalent to cloxacillin pour Bacterial infection of joint Therapeutic equivalent to cloxacillin pour Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin pour Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Therapeutic equivalent to cloxacillin pour Sepsis without septic shock

Oxazolindinones

Section	Indications
Reserve group antibiotics ◦ .	Other specified bacterial diseases

P-aminosalicylate sodium

Section	Indications
Antituberculosis medicines ◦ Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution	Multi-drug resistant Mycobacterium tuberculosis

P-aminosalicylic acid

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 4 g granules in sachet	Multi-drug resistant Mycobacterium tuberculosis

Phenoxymethylpenicillin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid ◦ Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt) ◦ Oral > Solid: 250 mg (as potassium salt) tablet	**Premier choix** Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Periapical abscess without sinus Acute pharyngitis **Autres indications** Bacterial infection of unspecified site

Piperacillin + tazobactam

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection	**Premier choix** Other specified pneumonia (Hospital-acquired pneumonia) Neutropaenia (high-risk) Peritoneal abscess (severe) Peritonitis (severe) co-prescrite avec clindamycin Necrotising fasciitis

Plazomicin

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 500 mg per 10 mL	Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Other carbapenem resistant Enterobacterales Carbapenem resistant Escherichia coli Carbapenem resistant Klebsiella pneumoniae

Polymyxin B (injection)

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)	Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Acinetobacter baumannii Other carbapenem resistant Enterobacterales Carbapenem resistant Klebsiella pneumoniae Carbapenem resistant Escherichia coli

Polymyxins

Section	Indications
Reserve group antibiotics ◦ .	Other specified bacterial diseases

Pretomanid

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > tablet: 200 mg	Multi-drug resistant Mycobacterium tuberculosis

Procaine benzylpenicillin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection	**Premier choix** Congenital syphilis [children] **Second choix** Syphilis

Protionamide

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > tablet: 250 mg (scored)	Therapeutic equivalent to ethionamide pour Multi-drug resistant Mycobacterium tuberculosis

Pyrazinamide

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 150 mg ◦ Oral > Solid > tablet: 400 mg; 500 mg	Tuberculosis

Rifabutin

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 150 mg	Tuberculosis

Rifampicin

Section	Indications
Antituberculosis medicines ◦ Parenteral > General injections > IV: 600 mg in vial powder for injection ◦ Oral > Liquid: 20 mg per mL ◦ Oral > Solid: 150 mg; 300 mg	Other specified tuberculosis Tuberculosis
Antileprosy medicines ◦ Oral > Liquid: 20 mg per mL ◦ Oral > Solid: 150 mg; 300 mg	Leprosy

Rifapentine

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > dispersible tablet: 150 mg ◦ Oral > Solid > tablet: 150 mg; 300 mg	Latent tuberculosis Tuberculosis

Spectinomycin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection	**Second choix** Gonococcal infection **Autres indications** Bacterial infection of unspecified site

Streptomycin (injection)

Section	Indications
Antituberculosis medicines ◦ Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial	Multi-drug resistant Mycobacterium tuberculosis

Sulfamethoxazole + trimethoprim

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule ◦ Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid ◦ Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet ◦ Oral > Solid > dispersible tablet: 100 mg + 20 mg ◦ Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule	**Premier choix** Infectious cystitis **Second choix** Infectious gastroenteritis or colitis without specification of infectious agent **Autres indications** Bacterial infection of unspecified site

Tedizolid

Section	Indications
Reserve group antibiotics	Therapeutic equivalent to linezolid pour Methicillin resistant Staphylococcus aureus Therapeutic equivalent to linezolid pour Vancomycin resistant Staphylococcus aureus Therapeutic equivalent to linezolid pour Vancomycin resistant Enterococcus

Terizidone

Section	Indications
Antituberculosis medicines ◦ Oral > Solid > capsule: 250 mg	Therapeutic equivalent to cycloserine pour Multi-drug resistant Mycobacterium tuberculosis

Tetracycline

Section	Indications
Access group antibiotics ◦ Oral > Solid: 250 mg (hydrochloride)	Bacterial infection of unspecified site

Tigecycline

Section	Indications
Reserve group antibiotics ◦ Parenteral > General injections > IV: 50 mg in vial powder for injection	Other specified bacterial diseases

Trimethoprim

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 50 mg per mL ◦ Oral > Solid: 100 mg; 200 mg	**Premier choix** Infectious cystitis

Vancomycin

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection ◦ Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride) ◦ Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection ◦ Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection	**Premier choix** Necrotising fasciitis co-prescrite avec ceftazidime Endophthalmitis co-prescrite avec ceftriaxone Endophthalmitis **Second choix** Intestinal infections due to Clostridioides difficile Neutropaenia (high-risk) **Autres indications** Methicillin resistant Staphylococcus aureus